Julia Meidenbauer1,2,3
Matthias Wachter1,2,3Sebastian R. Schulz4
Nada Mostafa1,2,3
Lilli Zülch1,2,3
Benjamin Frey1,2,3,5,6
Rainer Fietkau2,3,5,6
Udo S. Gaipl1,2,3,5,6
Tina Jost1,2,3*- 1Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 2Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 3Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nürnberg (EMN), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 4Division of Molecular Immunology, Internal Medicine III, University Hospital Erlangen, Nikolaus-Fiebiger Center, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
- 5Deutsches Zentrum Immuntherapie, Uniklinikum Erlangen, Erlangen, Germany
- 6FAU Profile Center Immunomedicine Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
by Meidenbauer J, Wachter M, Schulz SR, Mostafa N, Zülch L, Frey B, Fietkau R, Gaipl US and Jost T (2024) Front. Oncol. 14:1460150. doi: 10.3389/fonc.2024.1460150
In the published article, there was an error in the Funding statement. In the Funding statement one sentence was missing. The correct Funding statement appears below.
“The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the DFG Doctoral Training Group 2599 “Fine-Tuners of the Adaptive Immune Response” and partly by the Interdisciplinary Center for Clinical Research (IZKF) in Erlangen. The present work was performed by Julia Meidenbauer in (partial) fulfilment of the requirements for obtaining the degree “Dr. med.” at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: HNSCC, DNA damage repair, kinase inhibitors, immunomodulation, ATM inhibition, ATR inhibition
Citation: Meidenbauer J, Wachter M, Schulz SR, Mostafa N, Zülch L, Frey B, Fietkau R, Gaipl US and Jost T (2025) Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC. Front. Oncol. 15:1607882. doi: 10.3389/fonc.2025.1607882
Received: 08 April 2025; Accepted: 09 April 2025;
Published: 23 April 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Meidenbauer, Wachter, Schulz, Mostafa, Zülch, Frey, Fietkau, Gaipl and Jost. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tina Jost, dGluYS5qb3N0QHVrLWVybGFuZ2VuLmRl